The company posted drug sales of E258m, an increase of 6.3 percent, compared to E242.8m for the year ago period. This performance was driven by strong specialty care sales, with all products growing double digit: oncology, endocrinology and neurology grew 11.4, 23.3 and 16 percent excluding foreign exchange impacts respectively over the period.

Specialty care sales reached E168.5m, up 17.1 percent year-on-year, and its relative weight in total drug sales grew to 65.3 percent from 59.3 percent a year earlier. Primary Care sales reached E89.5m, down 9.5 percent year-on-year, impacted by slower sales in France notably.

Jean-Luc Belingard, chairman and CEO of Ipsen, said: “Ipsen’s specialty care franchise is more than ever confirming its high growth potential and has passed a landmark, as it now represents nearly two thirds of Ipsen’s total drug sales.

“In the near future, capitalizing on these positive developments, Ipsen will continue to progress its rich R&D pipeline, optimize the contribution of its presence in primary care and strengthen its R&D organization.”

Will Ipsen further improve sales in Q2?

Have your say and discuss with your peers on the InfoGrok community.

Participate by posting your comments now.